Angelo V Marzano
Overview
Explore the profile of Angelo V Marzano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
194
Citations
1696
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gargiulo L, Ibba L, Narcisi A, Giordano S, Maronese C, Martora F, et al.
Dermatol Pract Concept
. 2024 Dec;
14(4).
PMID: 39652961
Introduction: Psoriasis and hidradenitis suppurativa (HS) are chronic inflammatory diseases with significant overlap in their immunologic pathways, which involve cytokines such as tumor necrosis factor-alfa, interleukin (IL)-17, and IL-23. Current...
12.
Rossi M, Ferrucci S, Calzavara-Pinton P, Marzano A, Peris K, Nicoli E, et al.
Adv Ther
. 2024 Nov;
42(1):94-105.
PMID: 39546252
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition that can have a negative impact on a patient's quality of life. Long-term effectiveness is required to manage the symptoms...
13.
Lasagni G, Tavoletti G, Maronese C, Chiei Gallo A, Marzano A, Ferrucci S
Ital J Dermatol Venerol
. 2024 Nov;
159(6):697-698.
PMID: 39495496
No abstract available.
14.
Zouboulis C, Kyrgidis A, Alavi A, Jemec G, Martorell A, Marzano A, et al.
J Eur Acad Dermatol Venereol
. 2024 Oct;
PMID: 39425517
Introduction: The International Hidradenitis Suppurativa Severity Score System (IHS4) is a validated tool that measures inflammatory lesions, including draining tunnels, in hidradenitis suppurativa (HS). Objective: To evaluate secukinumab efficacy using...
15.
Chiei-Gallo A, Barei F, Calzari P, Pisapia A, Marzano A, Ferrucci S
Int J Dermatol
. 2024 Oct;
64(3):604-606.
PMID: 39397252
No abstract available.
16.
Valenti M, Ibba L, Cascio Ingurgio R, Malagoli P, Carugno A, Campoli M, et al.
Dermatol Ther (Heidelb)
. 2024 Oct;
14(11):2987-2997.
PMID: 39397217
Introduction: Guselkumab, a human monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown efficacy in psoriasis and psoriatic arthritis. However, long-term real-world data on its effectiveness in patients...
17.
Five-year real-world drug survival of dupilumab in severe atopic dermatitis and associate predictors
Barei F, Calzari P, Valtellini L, Chiei Gallo A, Perego G, Tavecchio S, et al.
J Dermatolog Treat
. 2024 Oct;
35(1):2404718.
PMID: 39396818
Background: Atopic dermatitis (AD) profoundly impacts patients' lives, necessitating long-term systemic treatments. Methods: This retrospective study involved 709 severe AD patients receiving dupilumab. Drug survival (DS) was analyzed using Kaplan-Meier...
18.
Chiei-Gallo A, Barei F, Calzari P, Pisapia A, Marzano A, Ferrucci S
Clin Exp Dermatol
. 2024 Oct;
50(3):659-662.
PMID: 39388584
No abstract available.
19.
Aromolo I, Rocca L, Benaglia C, Simeoli D, Perego G, Cattaneo A, et al.
Ital J Dermatol Venerol
. 2024 Sep;
160(1):79-80.
PMID: 39250165
No abstract available.
20.
Avallone G, Bombelli A, Termini D, Chiei-Gallo A, Barei F, Marzano A, et al.
Clin Exp Dermatol
. 2024 Aug;
PMID: 39140207
No abstract available.